Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Orthopedics Inflammation Immune Disorders

GSK and Janssen wade into competitive RA market with Phase III sirukumab program

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline and Janssen Biologics kicked off the Phase III program for their interleukin-6 (IL-6) inhibitor sirukumab (CNTO 136), which would compete with relative newcomers in the competitive rheumatoid arthritis market – Genentech's Actemra (tocilizumab), the first IL-6 inhibitor approved to treat patients with moderately to severely active rheumatoid arthritis, and Pfizer's novel oral Janus kinase (JAK) inhibitor tofacitinib.

Table

View full table

Topics

Related Companies

Tags:
Orthopedics Inflammation Immune Disorders
Latest Headlines

Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara

Humira Market Erosion Is Continuing As Expected, AbbVie Says

Pfizer Matches Beqvez Price To Hemgenix In Hemophilia B, Plans Warranty Program

Analysis: Novo And Lilly Make Their Money Work

See All
UsernamePublicRestriction

Register

SC018556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By